UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of February, 2023

(Commission File No. 001-41157)

 

BIONOMICS LIMITED

(Translation of registrant’s name into English)

 

200 Greenhill Road

Eastwood SA 5063

Tel: +618 8150 7400

(Address of registrant’s principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

Yes ☐ No ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

Yes ☐ No ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☐

 

 

 


 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

 

In regard to a General Meeting held in Australia on February 21, 2023, the Company has lodged the Results of the Meeting with the Australian Securities Exchange (ASX), as required by the laws and regulations of Australia. That document is furnished herewith as Exhibit 99.1 to this report on Form 6-K.

1


 

EXHIBIT INDEX

 

 

 

Exhibit

 

Description

 

99.1

2023 Results of General Meeting

 

 

 

 

 

2


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

 

 

 

 

Bionomics Limited

 

(Registrant)

 

 

 

 

By:

/s/ Errol De Souza

 

 

Name:

Errol De Souza, Ph.D.

 

Title:

Non-Executive Chairman

Date: February 21, 2023

 

1


Exhibit 99.1

 

 

 

 

img65882896_0.jpg 

ABN 53 075 582 740

 

21 February 2023

 

ASX Market Announcements ASX Limited

Level 4

Stock Exchange Centre 20 Bridge Street

SYDNEY NSW 2000

 

Dear Sir/Madam,

 

RESULTS OF ANNUAL GENERAL MEETING

 

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the attached document provides details of the proxies received and the manner in which votes were cast for each resolution.

 

This announcement was authorised for release by the Company Secretary.

 

FOR FURTHER INFORMATION PLEASE CONTACT:

Ms Suzanne Irwin Company Secretary

+61 8 8150 7400

CoSec@bionomics.com.au

 

About Bionomics Limited

Bionomics Limited (ASX: BNO, Nasdaq: BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

www.bionomics.com.au

Bionomics Limited | 200 Greenhill Road, Eastwood, South Australia, +61 8 8150 7400, ABN: 53 075 582 740

 


 

BIONOMICS LIMITED

GENERAL MEETING

Tuesday, 21 February 2023

Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

 

Resolution details

Instructions given to validly appointed proxies

(as at proxy close)

Number of votes cast on the poll

(where applicable)

Resolution

Result

Resolution

Resolution

Type

For

Against

Proxy's

Discretion

Abstain

For

Against

Abstain*

Carried /

Not Carried

1.
Issue of Options to Dr Papapetropoulos

Ordinary

319,929,841

90.50%

32,120,106

9.09%

1,452,010

0.41%

427,437

-

321,381,851

90.91%

32,120,106

9.09%

427,437

-

Carried

2.
Issue of Options to Dr De Souza

Ordinary

318,690,124

90.23%

33,050,348

9.36%

1,452,010

0.41%

736,912

-

320,142,134

90.64%

33,050,348

9.36%

736,912

-

Carried

3.
Termination Benefits to Dr Papapetropoulos

Ordinary

322,245,358

91.22%

29,708,110

8.41%

1,331,032

0.37%

644,894

-

323,576,390

91.59%

29,708,110

8.41%

644,894

Carried

4.
Ratify prior issue of 115,384,680 shares

Ordinary

189,779,948

96.75%

2,002,072

1.02%

4,370,829

2.23%

157,776,545

-

194,150,777

98.98%

2,002,072

1.02%

157,776,545

Carried

‘*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.